inhA promoter mutations: A gateway to extensively drug-resistant tuberculosis in South Africa?

Muller B. ; Streicher E.M. ; Hoek K.G.P. ; Tait M. ; Trollip A. ; Bosman M.E. ; Coetzee G.J. ; Chabula-Nxiweni E.M. ; Hoosain E. ; Gey Van Pittius N.C. ; Victor T.C. ; Van Helden P.D. ; Warren R.M. (2011)


SETTING: Western Cape and Eastern Cape Provinces, South Africa. OBJECTIVE: To assess the potential association between the evolution of extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis and mutations in the inhA promoter or the katG gene. DESIGN: Analysis of the frequency distribution of isoniazid (INH) resistance conferring mutations in a population sample of drug-resistant isolates of M. tuberculosis. RESULTS: In the Western Cape and Eastern Cape Provinces, the percentage of isolates exhibiting inhA promoter mutations increased significantly from respectively 48.4% and 62.4% in multidrug-resistant tuberculosis (MDR-TB) isolates to 85.5% and 91.9% in XDR isolates. Data from the Western Cape revealed that significantly more XDR-TB isolates showed mutations in the inhA promoter than in katG (85.5% vs. 60.9%, P < 0.01), while the respective proportions were equal for INH-resistant non-MDR-TB isolates (∼30%). CONCLUSIONS: inhA promoter mutations are strongly associated with XDR-TB in South Africa. We suggest that this is due to the dual resistance to ethionamide and (low-dose) INH conferred by inhA promoter mutations. The use of molecular probe assays such as the Geno-Type® MTBDRplus assay, which allows the detection of inhA promoter mutations, could enable treatment regimens to be adjusted depending on the pharmacogenetic properties of the mutations detected. © 2011 The Union.

Please refer to this item in SUNScholar by using the following persistent URL:
This item appears in the following collections: